Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study (Q40367786)
Jump to navigation
Jump to search
scientific article published on 26 January 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study |
scientific article published on 26 January 2010 |
Statements
1 reference
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study (English)
1 reference
Hartmut Döhner
1 reference
Bob Löwenberg
1 reference
Pieter Sonneveld
1 reference
Alois Gratwohl
1 reference
Johan Maertens
1 reference
Harry C Schouten
1 reference
Gregor Verhoef
1 reference
Joachim Beck
1 reference
Carlos Graux
1 reference
Wim van Putten
1 reference
Leo F Verdonck
1 reference
Augustin Ferrant
1 reference
Mojca Jongen-Lavrencic
1 reference
Marie von Lilienfeld-Toal
1 reference
Bart J Biemond
1 reference
Edo Vellenga
1 reference
Dimitri Breems
1 reference
Hilde de Muijnck
1 reference
Ron Schaafsma
1 reference
Thomas Pabst
1 reference
Gert J Ossenkoppele
1 reference
Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
1 reference
German Austrian AML Study Group (AMLSG)
1 reference
Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
1 reference
26 January 2010
1 reference
2586-2591
1 reference
Identifiers
1 reference